• Live
    • Audio Only
  • google plus
  • facebook
  • twitter
  • A woman gets COVID-19 test at a makeshift test site in Kew Gardens, one of the COVID-19 hotspot areas in New York City, the United States, Oct. 6, 2020.

    A woman gets COVID-19 test at a makeshift test site in Kew Gardens, one of the COVID-19 hotspot areas in New York City, the United States, Oct. 6, 2020. | Photo: Xinhua/Wang Ying

Published 29 October 2020
Opinion

"We are actively preparing for the launch of mRNA-1273 and we have signed a number of supply agreements with governments around the world," said Moderna CEO.

American biotechnology company Moderna said on Thursday it is preparing for the launch of its COVID-19 vaccine candidate globally.

"We are actively preparing for the launch of mRNA-1273 and we have signed a number of supply agreements with governments around the world," said Moderna CEO Stephane Bancel in a statement.

RELATED:
 Moderna: Final Clinical Trial for COVID-19 Vaccine in Late July

In addition to the Phase 3 study of the COVID-19 vaccine mRNA-1273, which is fully enrolled, Moderna now has four programs in Phase 2 studies, according to Bancel.

"Moderna is committed to the highest data quality standards and rigorous scientific research as we continue to work with regulators to advance mRNA-1273," he said.

On Oct. 22, the Phase 3 study of mRNA-1273 completed enrollment of 30,000 participants with approximately 37 percent of participants from diverse communities.

The Phase 1 interim analysis of the vaccine, published in The New England Journal of Medicine on July 14, showed that mRNA-1273 was generally well-tolerated across all age groups and induced rapid and strong immune responses against SARS-CoV-2.

Comment
0
Comments
Post with no comments.